
Molbio Diagnostics IPO
- Issue price
- ₹807
- Listing price
- ₹980
- +21.44%
- Current price
- ₹1,493.2
- +85.03%
- Subscribed
- 70.26x
- Issue size
- ₹939.7 Cr
- Listed on
- 17 Aug 2026
IPO timeline
- Opens10 AugMon
- Closes12 AugWed
- Allotment13 AugThu
- Refunds14 AugFri
- Demat credit14 AugFri
- Listing17 AugMon
Issue details
- Price band
- ₹768 – ₹807 per share
- Issue size
- ₹939.7 Cr
- Fresh issue
- Not available
- Offer for sale
- Not available
- Issue type
- Fresh capital cum OFS
- Face value
- ₹1 per share
- Lot size
- 18 shares
- Minimum investment
- ₹14,526
- Listing on
- BSE, NSE
- Exchange code
- MOLBIO · 7875
This issue combines a fresh issue and an offer for sale. The amounts for each part are not available in our data; see the offer document for the split.
Lot size and investment
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 18 | ₹14,526 |
| Retail (Max) | 13 | 234 | ₹1,88,838 |
| S-HNI (Min) | 14 | 252 | ₹2,03,364 |
| B-HNI (Min) | 69 | 1,242 | ₹10,02,294 |
Reservation
- QIB
- 23,25,146 shares
- NII
- 17,43,859 shares (21.43% of the Offer)
- Retail
- 40,69,004 shares (50.00% of the Offer)
- Employee
- 20,520 shares (0.25% of the Offer)
Allotment status
The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).
Check allotment on KFin Technologies- 1Open the registrar's allotment page and select this IPO from the list.
- 2Enter your PAN, application number or DP / Client ID.
- 3Submit to see the number of shares allotted, if any.
- Basis of allotment
- 13 Aug 2026
- Refunds initiated
- 14 Aug 2026
- Shares credited to demat
- 14 Aug 2026
- Listing
- 17 Aug 2026
Grey market premium (GMP)
- Current GMP
- ₹120
- +14.87%
- Estimated listing price
- ₹927
- Issue price ₹807
- Highest
- ₹220
- 6 Aug
- Lowest
- ₹115
- 14 Aug
GMP by day (₹ per share)
Day-wise GMP table
| Date | GMP | Premium | Est. listing |
|---|---|---|---|
| 17 Aug 2026 | ₹120 | +14.87% | ₹927 |
| 16 Aug 2026 | ₹120 | +14.87% | ₹927 |
| 15 Aug 2026 | ₹125 | +15.49% | ₹932 |
| 14 Aug 2026 | ₹115 | +14.25% | ₹922 |
| 13 Aug 2026 | ₹156 | +19.33% | ₹963 |
| 12 Aug 2026 | ₹154 | +19.08% | ₹961 |
| 11 Aug 2026 | ₹138 | +17.10% | ₹945 |
| 10 Aug 2026 | ₹127 | +15.74% | ₹934 |
| 9 Aug 2026 | ₹132 | +16.36% | ₹939 |
| 8 Aug 2026 | ₹130 | +16.11% | ₹937 |
| 7 Aug 2026 | ₹180 | +22.30% | ₹987 |
| 6 Aug 2026 | ₹220 | +27.26% | ₹1,027 |
| 5 Aug 2026 | ₹120 | +14.87% | ₹927 |
GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.
Subscription status
- QIB186.39x
- NII (HNI)49.8x
- Retail12.96x
- Employee13.28x
| Category | Shares offered | Shares bid for | Subscribed |
|---|---|---|---|
| Qualified Institutional Buyers (QIB) | 23,25,145 | 43,33,82,148 | 186.39x |
| Non-Institutional Investors (NII) | 17,43,860 | 8,68,40,604 | 49.8x |
| bNII — bids above ₹10 Lakh | 11,62,574 | 5,90,76,594 | 50.82x |
| sNII — bids ₹2 Lakh to ₹10 Lakh | 5,81,286 | 2,77,64,010 | 47.76x |
| Retail Individual Investors (RII) | 40,69,005 | 5,27,19,318 | 12.96x |
| Employee | 20,519 | 2,72,466 | 13.28x |
| Total | 81,58,529 | 57,32,14,536 | 70.26x |
Financials
- P/E Ratio
- 56.67
- EPS (₹)
- 14.24
- RoE
- 15.59%
- RoCE
- 17.55%
- RoNW
- 14.55%
- PAT Margin
- 11.28%
- EBITDA Margin
- 22.56%
- NAV (₹)
- 101.51
Separate pre- and post-issue P/E are not available for this IPO; the P/E shown is as disclosed for the issue.
| Period ended | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 2,148.42 | 1,461.56 | 1,221.06 |
| Total Income | 1,455.17 | 1,027.94 | 840.66 |
| Profit After Tax | 164.14 | 138.58 | 83.54 |
| EBITDA | 328.24 | 256.64 | 185.09 |
| NET Worth | 1,144.68 | 952.95 | 807.94 |
| Reserves and Surplus | 1,148.84 | 990.84 | 845.48 |
| Total Borrowing | 412.64 | 123.16 | 174.58 |
Peer comparison
| Company | Issue size | P/E | RoNW | PAT margin | Subscribed | Listing gain |
|---|---|---|---|---|---|---|
| Molbio Diagnostics This IPO | ₹939.7 Cr | 56.67 | 14.55% | 11.28% | 70.26x | +21.44% |
| Park Medi World Mainboard · listed 17 Dec 2025 | ₹920 Cr | 63.52 | 13.19% | 8.88% | 8.1x | -1.98% |
| Sudeep Pharma Mainboard · listed 28 Nov 2025 | ₹895 Cr | 53.55 | 27.88% | 27.63% | 93.72x | +23.10% |
| Nephrocare Health Services Mainboard · listed 17 Dec 2025 | ₹871.05 Cr | 162.19 | 13.19% | 8.88% | 13.96x | +6.52% |
| Ellenbarrie Industrial Gases Mainboard · listed 1 Jul 2025 | ₹852.53 Cr | 67.69 | 24.97% | 23.90% | 22.47x | +21.50% |
| Suraksha Diagnostic Mainboard · listed 6 Dec 2024 | ₹846.25 Cr | 74.89 | 14.09% | 10.57% | 1.27x | -0.68% |
| Medi Assist Healthcare Services Mainboard · listed 23 Jan 2024 | ₹1,171.58 Cr | 31.8 | 19.63% | 14.51% | 16.25x | +10.05% |
Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.
IPO objectives
How Molbio Diagnostics plans to use the money raised, as stated in the offer document.
- Funding capital expenditure towards the setting up of infrastructure for research and development facility, Center of Excellence and connected office space.₹125.12 Cr
- Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and₹80.81 Cr
- General Corporate Purposes
About Molbio Diagnostics
Molbio Diagnostics Limited was started in October 2000. It is a global point-of-care molecular diagnostics company. It does research, development, manufacturing and selling of quick diagnostic solutions for infectious diseases as well as non-communicable diseases. Its main product is the Truenat platform. This is a portable, battery-operated PCR based molecular testing system. It is made for places where lab facilities are limited, and it gives accurate results within an hour. The company offers testing for more than 30 diseases through 43 diagnostic tests. These include tuberculosis, COVID-19, HIV, Hepatitis B and C, and HPV. Through its subsidiaries and tie-ups, it also provides radiology, digital pathology and breast health screening solutions. It keeps adding new products through its own R&D. The company runs six manufacturing plants in India and serves customers in over 90 countries. Its customers include government health programmes, diagnostic labs, hospitals and international healthcare bodies. It holds a good number of patents and global certifications, and has grown through some strategic acquisitions. As on 31 March 2026, the company had 1,225 permanent employees across R&D, manufacturing, quality, sales, finance and corporate functions.
Strengths
- Truenat is its own patented platform. It is portable, runs on battery and gives PCR results in about an hour, which makes molecular testing possible in small towns and villages where full labs are not available.
- The product range is deep. It covers more than 30 diseases through 43 tests, including TB, HIV, Hepatitis B and C, and HPV.
- Reach is global. The company sells in more than 90 countries and runs six manufacturing plants in India.
- Growth has been strong. Total income went up from Rs 840.66 crore in FY2024 to Rs 1,455.17 crore in FY2026, and profit after tax almost doubled from Rs 83.54 crore to Rs 164.14 crore.
- Return ratios are healthy. RoCE was 20.98% and RoNW was 15.23%. EBITDA for FY2026 was Rs 328.24 crore.
- The fresh money goes into building the business. Rs 125.12 crore is for an R&D facility and a Centre of Excellence, and Rs 80.81 crore is for plant and machinery at Goa Unit I, Goa Unit II and the Visakhapatnam unit.
Risks
- Most of the issue is an offer for sale. Out of Rs 939.70 crore, about Rs 739.70 crore is OFS. The company will get only around Rs 200 crore for its own growth.
- The issue is priced high. At the upper band of Rs 807, the P/E is about 56.67 times on an EPS of Rs 14.24.
- Borrowings have gone up sharply. Total borrowing rose from Rs 123.16 crore in FY2025 to Rs 412.64 crore in FY2026, more than three times in one year. None of the fresh issue money is set aside to repay this.
- Promoter holding is low. It was 44.89% before the issue and will fall further to 41.29% after listing.
- The company depends a lot on government health programmes, especially TB testing. A change in government tender policy, pricing or order size can hit revenue.
- Profit is growing slower than sales. Revenue went up 42% but profit after tax rose 18% between FY2025 and FY2026.
- Diagnostics is a heavily regulated business. The company needs approvals and certifications in every country it sells in, and any delay or loss of approval will affect sales.
- The company competes with large global diagnostics players who have deeper pockets for research and marketing.
Promoters and shareholding
Sriram Natarajan, Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram and Exxora Trading LLP
- Promoter holding, pre-issue
- 44.89%
- Promoter holding, post-issue
- 41.29%
Anchor investors
Registrar, lead managers and documents
Lead managers
Company contact
Plot No. L-46, Phase II-D, Verna Industrial Area, Verna, Salcete, South Goa, Goa, 403722
8326724888
investors@molbiodiagnostics.comMolbio Diagnostics IPO: common questions
1.When does the Molbio Diagnostics IPO open and close?
The Molbio Diagnostics IPO opens on 10 Aug 2026 and closes on 12 Aug 2026.
2.What is the price band of the Molbio Diagnostics IPO?
The price band is ₹768 – ₹807 per share, with a lot size of 18 shares and a minimum investment of ₹14,526.
3.What is the size of the Molbio Diagnostics IPO?
The issue size is ₹939.7 Cr (Fresh capital cum OFS).
4.What is the GMP of the Molbio Diagnostics IPO?
The last reported grey market premium is ₹120 per share as of 17 Aug 2026, 08:24 AM IST. GMP is unofficial and changes frequently.
5.When is the Molbio Diagnostics IPO allotment?
The basis of allotment is expected on 13 Aug 2026. Allotment status can be checked with the registrar, KFin Technologies Limited.
6.When will the Molbio Diagnostics IPO list?
The shares listed on 17 Aug 2026 on BSE, NSE.
7.Who is the lead manager of the Molbio Diagnostics IPO?
The book running lead managers are Motilal Oswal Investment Advisors, Kotak Mahindra Capital Company Limited, Jefferies India Private Limited, IIFL Capital Services Limited, and the registrar is KFin Technologies Limited.
8.What will the money raised in the Molbio Diagnostics IPO be used for?
As stated in the offer document, the proceeds are for: Funding capital expenditure towards the setting up of infrastructure for research and development facility, Center of Excellence and connected office space.; Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and; General Corporate Purposes.
9.How can my company launch an IPO like Molbio Diagnostics?
Start with an IPO readiness assessment: eligibility for the Main Board, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.
For business owners
Your company could be the next listing
Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.
- Eligibility check against NSE Emerge, BSE SME and Main Board norms
- Indicative valuation and issue size for your business
- A clear timeline from readiness to listing day
Check if your business can list
Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.
Prefer to talk? Call +91 92130 20393